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Abstract
Background: Genomic grade (GG) is a 97-gene signature which improves the accuracy and prognostic value of histological
grade (HG) in invasive breast carcinoma. Since most of the genes included in the GG are involved in cell proliferation, we
performed a retrospective study to compare the prognostic value of GG, Mitotic Index and Ki67 score.
Methods: A series of 163 consecutive breast cancers was retained (pT1–2, pN0, pM0, 10-yr follow-up). GG was computed
using MapQuant Dx(R).
Results: GG was low (GG-1) in 48%, high (GG-3) in 31% and equivocal in 21% of cases. For HG-2 tumors, 50% were classified
as GG-1, 18% as GG-3 whereas 31% remained equivocal. In a subgroup of 132 ER+/HER22 tumors GG was the most
significant prognostic factor in multivariate Cox regression analysis adjusted for age and tumor size (HR=5.23, p=0.02).
Conclusions: In a reference comprehensive cancer center setting, compared to histological grade, GG added significant
information on cell proliferation in breast cancers. In patients with HG-2 carcinoma, applying the GG to guide the treatment
scheme could lead to a reduction in adjuvant therapy prescription. However, based on the results observed and considering
(i) the relatively close prognostic values of GG and Ki67, (ii) the reclassification of about 30% of HG-2 tumors as Equivocal GG
and (iii) the economical and technical requirements of the MapQuant micro-array GG test, the availability in the near future
of a PCR-based Genomic Grade test with improved performances may lead to an introduction in clinical routine of this test
for histological grade 2, ER positive, HER2 negative breast carcinoma.
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Introduction
In early stage breast cancers, biological prognostic factors are
essential to provide more accurate information to patients and to
guide the indications of adjuvant treatments. Besides Estrogen
Receptor (ER), Progesterone Receptor (PR), and HER2 status,
tumor cell proliferation rate is a major biological prognostic factor
and predictive factor of response to chemotherapy [1]. However
the best assay to assess cell proliferation in clinical practice is still a
subject of debate. Mitotic Index (MI) and Ki67 score are widely
used. MI, defined as the number of mitoses per 10 high power
fields at the periphery of the tumor [2,3], bears the main part of
the prognostic value of the histological grade scoring system in
which it is included. This index is linked to both the percentage of
tumor cells undergoing mitosis and the duration of the cell-cycle,
considering that the M phase is only a short part of the cell-cycle
process. However MI does not reflect the doubling time of the
tumor. In a large meta-analysis of 85 studies [4], including
univariate and multivariate models and involving 7.021 patients,
the independent prognostic value of MI for breast cancer patients,
regarding the development of metastases or the occurrence of
death from cancer as endpoints has been confirmed. Nuclear Ki67
immuno-staining is the other proliferation marker widely assessed
in clinical practice. Ki67 protein is present during all active phases
of the cell cycle (G1, S, G2, M phases) and is strictly associated
with cell proliferation. Ki67 score is most often measured on
histological sections and is defined as the percentage of stained
invasive carcinoma cells. The prognostic value of Ki67 score has
been confirmed in several reviews and meta-analyses including
univariate and multivariate models [4,5,6,7]. However its use is
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35184hampered by several technical limitations, and no ideal cut-off can
so far be recommended for routine use [8].
High throughput molecular analyses are able to provide the
expression pattern of genes directly or indirectly linked to tumor
cells proliferation. The GG is a 97-gene expression signature
designed by Sotiriou et al to further discriminate, in the group of
histological grade II carcinoma, lesions biologically close to
histological grade I carcinoma from those close to grade III [9].
Most of these 97 genes are involved in proliferation and cell cycle
control. A high level of concordance between GG and histological
grade was observed for histological grade I and histological grade
III tumors [9,10]. In addition, in histological grade II tumors, the
GG was able to identify subsets of ‘‘HG 1 like’’ and ‘‘HG 3 like’’
tumors. Consistent with the prognostic value of histological grade,
the prognostic value of the GG was confirmed in several studies
[9,11,12,13]. Although the GG was primarily designed to improve
the discriminatory power of tumor grading of breast cancers, and
consistent with the fact that most of the GG genes are linked to
proliferation, this genomic index was also reported to be a
predictor of relapse in endocrine treated carcinoma [14] and a
predictor of histological complete response to primary chemo-
therapy in ER positive and ER negative breast carcinomas [15].
Since the GG is a genomic measure of cell proliferation, we
designed a study to assess the respective prognostic value of the
GGI, the MI and the Ki67 score in a series of pN0 early breast
cancer patients treated in a large comprehensive cancer centre and
followed for at least ten years.
Materials and Methods
Patients
The main inclusion criteria for the study were the absence of
pathologic axillary lymph node involvement, a follow up above 10
years, and the absence of neoadjuvant therapy before surgery.
Using these criteria, 456 early-stage (T1-T2 pN0) breast cancer
patients treated between 1995 and 1996 could be retrieved from
the Institut Curie database. From these cases, 169 flash-frozen
samples stored at 280uC immediately after lumpectomy or
mastectomy, and showing more than 50% of tumor cells at the
microscopic examination of frozen histological section, were
available. The histological features (Histological type, Histological
grade assessed according to Elston and Ellis criteria [2,3], Mitotic
Index, Ki67 staining, Estrogen Receptor status, Progesterone
Receptor status, HER2 over expression status) were re-assessed for
each sample by pathologists experienced in breast pathology.
Tissue samples were fixed in AFA. Tissue sections (4 mm) were
prepared from a representative part of each tumour sample to
score the following markers: Mitotic Index, Ki67, ER, PR, and
HER2.
Mitotic Index (MI)
Mitotic Index was assessed on histological sections stained by
Hematein, Eosin and Saffron. The criteria of Van Diest et al were
used to define mitotic figures [16,17]. It corresponds to the mitotic
score used in the Nottingham grade; the number of mitoses
observed in 10 consecutive high power fields (HPF) using a
microscope with a 406objectives and a 106ocular was counted.
Cut-offs of ,10, 10–19 and $20 mitosis were used to define low,
intermediate and high mitotic indexes.
Ki67 immunostaining
Tissue sections were first digested in 0.1% trypsin and 0.1%
calcium chloride in triphosphate buffer saline pH 7.6 for
5 minutes. Antigen retrieval was performed by incubating tissue
sections for 20 minutes in citrate buffer 10 mM (ph 6.1) in a
850 W microwave oven. Tissue sections were then incubated for
one hour with the anti-Ki67 monoclonal antibody (Clone MIB1,
Dako A/S, Glostrup, Denmark) at 1/100 dilution. The revelation
of the staining was performed using the Vectastain Elite ABC
peroxydase mouse IgG kit (Vector Burlingame, CA, USA) and
diamino-benzidine (Dako A/S) as chromogen. The semiquantita-
tive assessment was performed by estimating at 6200 magnifica-
tion, the percentage of positive neoplastic nuclei within the area of
highest positivity chosen after scanning the entire tumour surface
at low power (610 objective). All nuclei with homogeneous
staining even with a light staining or only a nucleolar staining were
interpreted as positive. A cut-off of .20% was used to define
tumors with high Ki67 score.
Estrogen Receptor, Progesteron Receptor
immunostaining
After rehydration and antigenic retrieval in citrate buffer
(10 mM, pH 6.1), the tissue sections were stained for estrogen
receptor (ER, clone 6F11, Novocastra, 1/200), and progesterone
receptor (PR, clone 1A6, Novocastra, 1/200). Revelation of
staining was performed using the Vectastain Elite ABC
peroxidase mouse IgG kit (Vector Burlingame, CA) and
diaminobenzidine (Dako A/S, Glostrup, Denmark) as chromo-
gen. Positive and negative controls were included in each slide
run. Cases were considered positive for ER and PR according to
standardized guidelines using a cut-off of $10% stained tumour
nuclei [18,19].
HER2 status
After rehydration and antigenic retrieval in citrate buffer
(10 mM, pH 6.1), the tissue sections were stained for HER-2
(clone CB11, Novocastra, 1/1000). Revelation of staining was
performed using the Vectastain Elite ABC peroxidase mouse
IgG kit (Vector Burlingame, CA) and diaminobenzidine (Dako
A/S, Glostrup, Denmark) as chromogen. Positive and negative
controls were included in each slide run. The determination of
HER2 overexpression was determined according to GEFPICS
guidelines with FISH performed in all cases of HER2 2+ result
[20].
Genomic Grade and Genomic Grade Index
All 169 tumour samples available for genomic grade analysis
contained more than 50% of cancer cells as assessed by H&E
staining on frozen histological section of the samples used for the
transcriptome analysis (manufacturer’s recommended threshold:
30%). RNA was extracted using Trizol method (Invitrogen)
according to manufacturer’s instruction and purified using
mirRNeasy kit (Qiagen). The concentration, integrity and purity
of each RNA sample (260/280, 260/230, 28S/18S, RIN) were
measured using RNA 6000 LabChip kit with the Agilent 2100
Bioanalyser (Agilent technologies, Palo Alto, CA). The DNA
microarrays used in this study were the Affymetrix HGU133
Plus 2.0 arrays (Affymetrix, Santa Clara, CA). One hundred
nanograms of total RNA were used for the IVT express target
preparation procotol. Details of the RNA amplification, labeling
and hybridization are available from the Affymetrix website
(http://www.affymetrix.com). Chips were scanned using the
GCS 3000 7G scanner (Affymetrix). Affymetrix quality controls
variables were used to check data homogeneity (average noise,
average background, percent present, scale factor, degradation
slope, GAPDH, b-actin). Outliers defined by 1.5 Inter Quartile
Range were flagged for each control. All Genechips had to meet
Genomic Grade and Proliferation Markers
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average noise and average background are flagged, 2) or the
scale factor and percent present are flagged, 3) or the
degradation slope is flagged, 4) or GAPDH and b-actin are
flagged. Profiles were normalized using RMAdx procedure.
RMA was applied to a reference set of microarrays (191 high-
quality profiles), storing the parameters of the RMA fit. To
process additional microarrays, these parameters are directly
applied, without any re-estimation.
Genomic Grade Calculation
The Genomic Grade Index (GGI), a continuous variable, was
calculated using the MapQuant DxM protocol, based on Sotiriou
et al [9], and defined as GGI=scale [sum (Probe Sets up in Grade
3 tumors)2sum (Probe Sets up in Grade1 tumors)2offset]. Scale
and offset are transformation parameters to standardize the
genomic grade index values. The MapQuant GGI was then
standardized by setting the scale and offset parameters from a
reference dataset (53 ER positive Histological Grade 1 vs 59 ER
positive Histological Grade 3), so that the mean GGI of histologic
grade 1 tumors was 21 and that of histologic grade 3 tumors was
+1. The cut-off was set at 0, with GGI varying between 23 and
+3. Based on the value of the GGI, a genomic grade (Genomic
Grade 1 or Genomic Grade 3) was then attributed to each tumor
sample. To ensure robustness and accuracy of genomic grading, a
statistical confidence interval was defined around the cut-off, based
on a 3:1 odds ratio of being GG-1 or GG-3 and validated using
precision data. For GGI values into this confidence interval, the
genomic grade is defined as ‘equivocal’.
Statistical Analysis
Baseline characteristics were compared between groups using
Chi-square or Fisher’s exact tests for categorical variables and
Student’s t-tests for continuous variables. Overall survival and time
to distant metastasis were defined as the time from diagnosis of
breast cancer until occurrence of the event. The ten-year follow-up
metastastic event predictive performance analysis of histological
grade, Genomic Grade Index, Mitotic index and Ki67 was carried
out using Area-Under-the-Curve analysis and the ROCR
package. Survival analyses were performed using the Kaplan-
Meier estimate of the survival function. Comparison between
survival curves was performed using the logrank test. Hazard
ratios were estimated using the Cox proportional hazard model. P-
values were considered significant when below 0.05. Ki67 and GG
were analysed first as continuous variables then as categorical
variables (the latter corresponding to the routine use of these 2
indexes). Adjustments by patient age and tumor size were used for
univariate and multivariate analyses. The analyses were performed
using the R software (http://cran.r-project.org).
Results
Pathological and Clinical Data
From the 169 cases available for analysis, 163 passed quality
controls and constituted the reference cohort. The clinical and
pathological features of these 163 cases are summarized in table 1.
Tumors corresponded mainly to ductal (78%) or lobular (13.5%)
infiltrating carcinoma. All of them were free of axillary lymph
node metastases. Tumors were classified as histological grade I in
32.5%, grade II in 43% and grade III in 24.5% of cases.
Immunophenotyping showed that ER was expressed in 85.8%
(140/163) of the tumors, PR in 68.7% (112/163), HER2 in 6.1%
(10/163) whereas 10.4% (17/163) remained negative for the three
markers. The median follow-up duration was 154 months (6–182)
and 26 patients (17.8%) developed a distant relapse.
Mitotic Index, Ki67 score and Genomic Grade distribution
The Kernel density plot shows a non-continuous and non-
homogeneous distribution of Mitotic Index (MI) and of Ki67
score. A majority of samples had a MI below 20 mitoses per ten
high power fields and a high MI ($20) was observed in 21.4%
(35/163) of the tumors. A high Ki67 score (.20%) was observed
in 43% (70/163) of the tumors (n=17 with Ki67=20%). The
GGI showed a continuous and homogeneous distribution (figure
S1), ranging from 22.618 to 3.035 with a mean equal to 20.1964
(22.95 to 21.78, mean=22.38 for normal breast tissue, data not
shown).
Comparison between the Genomic Grade and the
Histological Grade
Genomic Grade (GG) analysis showed that 47.8% of cases were
GG-1 (78/163) and 30.7% were GG-3 (50/163). The GG was
equivocal in 21.4% of the cases (35/163). The concordance
between GG and histological grade was 93% for GG-1 samples
(also histological grade I) and 97% for GG-3 (also histological
grade III). Among the 70 cases of histological grade II samples, 35
(50%) were reclassified as GG-1 and 13 (18.6%) as GG-3 whereas
31.4% remained equivocal (22/70). Conversely, about two third of
the undetermined GG corresponded to histological grade II
tumors (22/35). The clinical and pathological features of each
subgroup are summarized in tables 2 and 3. The following
variables were found significantly correlated to the following
combinations of Histological Grade and of Genomic Grade [HG-
1_GG-1/HG-2_GG-1/HG-2_GG-3/HG-3_GG-3]: histological
type, tumor size, vascular invasion, mitotic index, Ki67 score,
ER and PR status, triple negative status, metastatic events. The
presence of vascular invasion and Ki67 score were the only factors
significantly correlated to the GG when the analysis was restricted
to the subgroup of histological grade II tumors.
Comparison between the Genomic Grade, the Mitotic
Index and the Ki67 score
There was a strong positive association between the GG and the
MI (Chi-square test, p=2.3.10
216). The relation between the
continuous value of the GG and the MI is pictured in figure 1.
GG-1 samples were classified as MI I in 92.3% (72/78) of the cases
and GG-3 samples as MI III in 62% (31/50) cases (table 2). Two
thirds (23/35) of the equivocal GG cases corresponded to MI I
tumors. GG-3 samples had a low or intermediate MI in 19 out of
50 cases (38%) and only 1 out of 78 (1.3%) GG-1 samples had a
high MI.
The Ki67 score was also positively correlated to the GGI. The
relationship between the continuous value of the GGI and the
Ki67 is pictured in figure 1. It shows a linear interaction pattern
of these two variables (R=0.72, R
2=0.51). GG-1 samples were
classified as Ki67 low (#20%) in 88.4% (69/78) of the cases and
GG-3 samples as Ki67 high (.20) in 90% (45/50) (Chi-square
test, p value= 2.2e-16). Samples with an equivocal GG were
classified as Ki67 low in 54.3% (19/35) cases. When the three
markers were considered simultaneously, we observed that
tumors with high MI ($20) were almost exclusively classified
as GG-3 (30/31, 96.7%) independently of the Ki67 score
(table 3). Tumors with low MI (,20) and low Ki67 score (#20)
were almost exclusively classified as GG-1 (69/70, 98.5%). The
group of tumors with low MI and high Ki67 score showed a
uniform distribution between the 4 subclasses defined by the
Genomic Grade and Proliferation Markers
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1_GG-1/HG-2_GG-1/HG-2_GG-3/HG-3_GG-3]. Interac-
tions between GG, MI, Ki67 score and metastatic events are
depicted in figure S2.
Comparison between the Genomic Grade and
immunophenotypic subtypes of breast cancers
A total of 133 samples corresponded to ER positive HER2
negative tumors. Among them, 73 (54.8%) were GG-1, 29 (21.8%)
were GG-3 whereas 31 (23.3%) were equivocal GG. In the group
Table 1. Clinical and Pathological features of 163 pN0 early stage breast carcinomas.
Clinical and Pathological Features. (N=163)
Clinical and histological features Median (min-max) Number of cases (%)
Age at Diagnosis (years) 53 (26–70)
Histological Subtype
Infiltrating ductal 127 (78%)
Infiltrating lobular 22 (13.5%)
Mixed ductal/lobular 6 (3.7%)
Others 8 (5%)
Pathological Tumor Size (mm) 20 (7–45)
Lympho Vascular invasion 33 (20%)
Histological grade
Grade I 53 (32.5%)
Grade II 70 (43%)
Grade III 40 (24.5%)
Number of Mitoses (per ten HPF) 6 (0–120)
Ki67 (percent) 20 (0–100)
ER positive 140 (85.8%)
PR positive 112 (68.7%)
HER2 positive 10 (6.1%)
ER negative PR negative HER2 negative 17 (10.4%)
Hormone-therapy 17 (10.4%)
Chemotherapy 11 (6.7%)
Metastases Events 29 (17.8%)
Follow-up (months) 154 (6–182)
doi:10.1371/journal.pone.0035184.t001
Table 2. Two by two samples distribution.
GG-1 GG-EQ GG-3 MI1 MI2 MI3 Ki67 L Ki67 H
EE I 4 2 8 3 5 1 204 5 8
EE II 35 22 13 53 15 2 43 27
EE III 1 5 34 0 7 33 5 35
Ki67 L 69 19 5 81 8 4
Ki67 H 9 1 6 4 5 2 31 63 1
MI1 72 23 9
MI2 59 1 0
MI3 13 3 1
GG-I GG-EQ GG-III HGI HGII HGIII
ER+ HER22 73 31 29 52 60 21
ER2PR2HER22 10 1 6 0 31 4
HER2+ 23 5 0 64
GG: Genomic Grade. HG: Histological Grade. Ki67 L: Ki67#20%. Ki67 H: Ki67.20%. MI: Mitotic Index [Elston Ellis. MI1: 0 to 9 mitosis/high power field (hpf). MI2: 10 to 19
mitosis/hpf. MI3.20 mitosis/hpf].
doi:10.1371/journal.pone.0035184.t002
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were undetermined GG. Among the 17 triple negative (ER2,
PR2, HER22) tumors, 1 was classified as GG-1 and 16 as GG-3.
It is to be stressed that the proportion of equivocal GGI samples
was lower (0%) in the group of triple negative tumors than in
HER2 positive (30%) or ER positive (23.3%) subgroups. The
status of the histological grade in all of these groups is provided in
table 2.
Table 3. Clinical and Histological features of pN0 early stage breast carcinomas according to histological grade and to Genomic
Grade Index.
Clinical and Pathological features according to Histological Grade and Genomic Grade Index.
HG I
GG-1
HG II
GG-1
HG II
GG-3
HG III
GG-3 p value p value*
Number of cases 42 35 13 34
Age (years) Median (Range) 54 (41–70) 57 (40–70) 55 (40–63) 51 (26–68) NS NS
Histology. N (%)
IDC 33 (78.5) 24 (68.6) 11 (84.6) 30 (88.2) 5.10
22 NS
ILC 3 (7) 10 (28.6) 2 (15.4) 2 (5.8)
ILC/IDC 2 (4.7) 1 (2.8) 0 1 (2.9)
Others 4 (9.5) 0 0 1 (2.9)
Tumor Size (mm) 15 (7–35) 20 (10–35) 20 (10–30) 23 (10–45) 2.10
23 NS
Vascular invasion. N (%) 4 (9) 5 (14.3) 7 (53.8) 8 (23.5) 3.10
23 1.4.10
22
High MI ($20). N (%) 0 0 1 (7.7) 30 (88.3) 2.10
216 NS
High Ki67 (.20%). N (%) 3 (7.1) 5 (14.2) 12 (92.3) 30 (88.2) 2.10
211 3.10
24
Low MI/low Ki67. N (%) 39 (92.8) 30 (85.7) 1 (7.6) 0 2.10
216 2.10
24
Low MI/high Ki67. N (%) 3 (7.1) 5 (14.2) 11 (84.6) 4 (11.7)
High MI/low Ki67. N (%) 0 0 0 4 (11.7)
High MI/high Ki67. N (%) 0 0 1 (7.6) 26 (76.4)
ER positive. N (%) 41 (97.6) 33 (94.3) 10 (76.9) 18 (52.9) 6.10
26 NS
PR positive. N (%) 31 (73.8) 28 (80) 9 (69.2) 12 (35.3) 4.10
24 NS
HER2 positive. N (%) 0 2 (5.7) 2 (15.3) 3 (8.8) NS NS
ER2/PR2/HER22. N (%) 0 1 (2.8) 2 (15.4) 14 (41.2) 5.10
27 NS
Metastatic events. N (%) 3 (7) 3 (8.5) 3 (23) 9 (26.4) 5.10
22 NS
HG: histological grade. GG: Genomic Grade. IDC: Infiltrating Ductal Carcinoma. ILC: Infiltrating Lobular Carcinoma. MI: Mitotic Index. Low MI, MI,20. High MI, MI.=20.
ER: Estrogen Receptor. PR: Progesterone Receptor. Chi-square test, Fisher exact test, Student’s t-test p values as adapted.
*pvalue in the four groups.
**p value in the group of histological grade II tumors only. HGI GG-EQ, HG-1 GG-3, HG-3 GG-EQ and HG-3 GG-1 samples are excluded from this table.
doi:10.1371/journal.pone.0035184.t003
Figure 1. Comparison between Genomic Grade Index, Mitotic Index and Ki67 score. Left. Scatter plot of Genomic Grade Index (GGI) and
Ki67 score. Red dot: GG-3 samples; Black dot: GG-Equivocal; Green dot: GG-1. Right. Scatter plot of GGI and Mitotic Index. Red dot: GG-3; Black dot:
GG-Eq; Green dot: GG-1. Horizontal stripes: thresholds for GG-1 (upper line) and GG-3 (lower line).
doi:10.1371/journal.pone.0035184.g001
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At 10 years of follow-up, the three proliferation markers were
found to be associated with the probability of metastatic events.
The GGI had the highest Area Under Curves (AUC) values in the
overall population of tumors as well as in the different subgroups
determined according to histological grade and molecular
subtypes immune-phenotype, but there was no significant
statistical difference between the three proliferation markers nor
with Histologic Grade (Hanley’s test) (table 4, figure 2). The largest
differences were seen in the group of ER positive HER2 negative
tumors with AUC at 0.77 for GGI [0.66–0.88], 0.69 for Ki67
[0.58–0.80], and 0.63 for MI [0.52–0.74]. In the subgroup of 70
histological grade II tumors, none of the 3 proliferation markers
accurately predicted the probability of metastasis (8 events) (table 4,
figure 3).
Kaplan-Mayer survival curves for 10-year distant metastasis free
survival were computed for GG, Ki67 score, MI and histological
grade for the ER+/HER2- population (figure 4). GG and Ki67
score were the only significant prognostic factors, with respective
relative risks of 4.01 (p=0.007) and 2.56 (p=0.04).
Cox proportional hazard regression analyses using clinical and
pathological features with 10-year distant metastasis free survival
as endpoint were performed for the 145 cases without systemic
chemotherapy and for the subgroup of 126 ER+/HER2-tumors
and no systemic chemotherapy. In order to evaluate the biological
relation between IHC Ki67 and GG, we performed a multivariate
analysis comparing Ki67 score and GGI as continuous variables.
It has to be recalled that GG is commercially available as a
categorical variable only. The GG was the only significant variable
in this model (HR=2.26; p=0.014). After adjustment for age at
diagnosis and tumor size, in univariate analysis, Ki67 score
(continuous and categorical), GG (continuous and categorical),
and MI (continuous only) were all significantly correlated to the
outcome (table 5). A multivariate analysis was performed to
determine if any of the proliferation markers would individually
add supplemental prognostic information to that provided by age,
tumor size and histological grade. We found that the three
markers, GG [categorical: HR=5.2 (1.3–21) p=0.02, and
Figure 2. Prediction of metastases events at 10 years of follow-
up from initial diagnosis. Receiver Operating Curves. 106 Estrogen
Receptor positive HER2 negative samples with 10-year follow-up data.
Blue: Genomic Grade Index (GGI); Red: Ki67; Black: Histological Grade
(HG); Pink: Mitotic Index (MI).
doi:10.1371/journal.pone.0035184.g002
Figure 3. Prediction of metastases events at 10 years of follow-
up from initial diagnosis. Receiver Operating Curves. 43 Histological
Grade II, ER positive samples with 10-year follow-up data. Blue:
Genomic Grade Index; Red: Ki67; Pink: Mitotic Index.
doi:10.1371/journal.pone.0035184.g003
Table 4. Prognostic values of Histological Grade, Genomic Grade Index, Ki67 score and Mitotic Index, regarding metastatic events
at 10 years of follow-up in biological subgroups of pN0 breast carcinoma.
Prognostic value of HG, GGI, Ki67, MI. AUC (95%CI).
Tumor groups N HG AUC [95%CI] GGI AUC [95%CI] Ki67 AUC [95%CI] MI AUC [95%CI]
All cases 106 0.63 [0.57–0.68] 0.74 [0.63–0.85] 0.7 [0.6–0.8] 0.64 [0.54–0.75]
ER+ 90 0.63 [0.56–0.69] 0.77 [0.67–0.88] 0.71 [0.6–0.81] 0.65 [0.55–0.75]
ER+/HER22 86 0.61 [0.54–0.68] 0.77 [0.66–0.88] 0.69 [0.58–0.8] 0.63 [0.52–0.74]
HG II 43 _ 0.64 [0.44–0.83] 0.58 [0.45–0.7] 0.52 [0.35–0.7]
ER+/HG II 39 _ 0.69 [0.49–0.89] 0.61 [0.48–0.75] 0.53 [0.36–0.7]
Receiving Operating Curves. Numbers correspond to Area Under Curves [95% Confidence Interval]. HG: histological grade; GGI: Genomic Grade Index; MI: Mitotic Index;
ER: Estrogen Receptor. N: Number.
doi:10.1371/journal.pone.0035184.t004
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ical: HR=3.28 (1.03–10.4) p=0.044] and MI [continuous:
HR=1.07 (1.01–1.14) p=0.024] were the significant prognostic
covariates in this model (table 5).
Treatment decision
We analyzed the potential effect of the Genomic Grade on use
of adjuvant systemic treatment and hormonal therapy in 70
histological grade II tumors using the current 2010 Institut Curie
adjuvant treatment guideline (table 6). When diagnosed in 1995–
1996, 11.4% of patients in our cohort actually received hormonal-
therapy, 2.8% received hormonal and chemotherapy while 85.7%
had no adjuvant treatment. The 2010 treatment decision
algorithm was firstly run using the histological grade, and secondly
the GG. Equivocal GG samples were considered as histological
grade 2. Based on histological grading, 5.7% of patients with
histological grade II tumors would have received adjuvant
chemotherapy (ACT) alone (all of them were ER2/PR2), 50%
would have received adjuvant hormonal therapy (AHT) alone,
and 44.3% both treatments. Using the GG, 20% of patients would
have been spared of ACT and 15% of AHT. In the ER+/HER22
subgroup (60 patients), 56.6% of patients would have received
AHT and 43.3% AHT+ACT based on histological grade; making
decision based on GG would have led to a 27% reduction in ACT
prescription and to a 16.6% reduction in AHT prescription.
Discussion
The value of tumor grade as one of the most robust prognostic
factors to guide adjuvant treatments in invasive breast cancer, and
more specifically in ER+ tumors, is established [21]. The
histological grade is used in most of the current treatment decision
algorithms [22,23,24,25]. However, about 40–50% of small size
node negative breast carcinoma are histological grade II, and there
is a lack of definite clinico-biological criteria to guide the
indications of adjuvant chemotherapy in this category which
currently represents one of the most frequent breast tumors at
diagnosis [21]. The Genomic Grade (GG) has been designed to
separate histological grade II carcinoma in either low risk (GG-1)
or high risk (GG-3) tumors, and therefore address this limitation of
histologic tumor grading [9]. At the 2009 St. Gallen consensus
conference, the genomic grade has been integrated as a potential
adjunct to histological grading and the Ki67 as a prognostic factor.
In order to assess the usefulness of the GG in clinical practice
compared to that of mitotic index (MI) and of Ki67 score, we have
analyzed the respective prognostic value of these parameters in a
retrospective study of 163 cases of small size pN0 invasive
carcinoma of the breast treated in a single institution between
1995 and 1996. There was a relative correlation between GG,
Ki67 score and MI values and these proliferation markers were
associated with similar pathological features. A linear correlation
was observed between GGI and Ki67. Ki67 gene is one gene out
of the 97 genes set that determines the GG signature and they are
both measure of proliferation. We also observed a log-linear
relation between GGI and MI. Major variations of MI were most
commonly observed in tumors with high GGI. Our study
confirmed that GG was a significant predictor of distant
metastases, more accurately in ER positive breast cancer patients,
a result already reported by others [12,13,26]. When restricted to
the group of histological grade II and ER+/HER22 carcinoma
Figure 4. Kaplan Meier Survival Curves. Distant Metastases Free Survival Analysis. 132 Estrogen Receptor positive HER2 negative samples.
Logrank tests pvalue. Top Left. Genomic Grade (GG). Green: GG-1. Red: GG-3. (p=0.007). Bottom Left. Histological Grade (HG). Green: HG-1. Red:
HG-3. (p =0.15). Top Right. Ki67 score. Green: Ki67#20%. Red: Ki67.20%. (p=0.04). Bottom Right. Mitotic Index (MI). Green: MI I. Red: MI III.
(p=0.12).
doi:10.1371/journal.pone.0035184.g004
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show any significant prognostic value in term of 10 years
metastasis events or in Cox proportional hazard model. This
negative result is probably due to the lack of statistical power in
this subgroup containing a limited number of cases and events. In
a set of 216 cases of histological grade II breast cancers, Sotiriou et
al found a better outcome of cases reclassified as GGI I than that
reclassified as GGI III [9].
The comparison between the values of proliferation markers
and disease outcome showed that GG and Ki67 were of quite
comparable prognostic value, higher than that of MI, for 10-year
metastasis free survival in this series of small size, node negative,
invasive breast carcinoma. In categorical analysis, the value of GG
was slightly higher than that of Ki67, but the difference was not
statistically significant. The prognostic value of Ki67 in breast
cancers has been validated in numerous studies [4,5,6,7].
However, the use of this marker in clinical practice has been
hampered by a lack of standardization in technical aspects and in
interpretation of the immuno-labeling. For instance, there still is
no widely accepted threshold to define high Ki67 score and
reported cut-off values vary between 5–30%, more frequently
between 10% and 20% [4,5,6,7]. In the present work we used
20% as a threshold for Ki67 score since this is the cut-off set in
clinical routine in our institution to discriminate between high and
low proliferation tumour. Furthermore, (ii) this value was also the
median of Ki67 scores in this series. This threshold has however to
be validated on larger series. The inter-observer reproducibility for
the scoring of the immuno-labeling has also to be confirmed,
especially for values close to the threshold. The use of image
analysis systems is likely to overcome this difficulty and to reduce
inter-observers variability for equivocal results [27].
In our series, 21% of all tumors, and 31% of Histologic Grade 2
tumors, were classified as Equivocal, i.e. their Genomic Grade
Index value fell between the GG-1 or GG-3 categories. The
definition of an Equivocal category improves performance of the
test around the cut-off point, and enhances the overall robustness
of the test, albeit at the expense of the number of samples
classified, esp. for Histologic Grade 2 tumors. The proportion of
HG-2 cases classified Equivocal could also be driven by the
grading performance of each centre, with HG-2 Equivocal cases
being higher in reference centres compared to non-expert centres.
By its design and validation, the Genomic Grade represents a
genomic measure of tumoral grade, and could therefore be used as
direct replacement of the Histologic Grade in current guidelines or
treatment algorithms. To explore this option, we replaced HG by
GG in the 2010 Institut Curie Treatment Guidelines. We have
shown that applying GG to the group of histological grade II and
ER+/HER22 tumors would have led to a 27% decrease in
adjuvant chemotherapy and a 16.6% decrease in hormonal
therapy prescriptions. We didn’t perform a similar analysis with
Ki67 as its position in treatment decision algorithms is not as well
as determined as that of tumoral grade. Furthermore Ki67 is not
intended to replace tumor grade even if it is closely related to it.
The data on Genomic Grade underline the medico-economic
Table 5. Prognostic values of Histological Grade, Genomic Grade, Ki67 score and Mitotic Index, regarding metastatic events.
Prognostic values of HG, GG, Ki67 rate and MI
HG3 vs HG1 GG3 vs GG1 Ki67 (High vs Low) MI 3 vs MI 1
HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI) P
Univariate 2.89 (0.6–13.7) 0.18 5.08 (1.5–17.3) 0.009 3.68 (1.3–10.6) 0.017 2.63 (0.7–8.7) 0.11
Multivariate Reference 5.23 (1.3–21) 0.02 3.28 (1.03–10.4) 0.044 7.77 (0.8–70) NS
Cox Model, categorical analysis.
HG: histological grade; GG: Genomic Grade; MI: Mitotic Index; ER: Estrogen Receptor. HR: Hazard Ratio. Multivariate Analysis. GG, Ki67 and MI are individually compared
to the Histological Grade as defined by Elston Ellis as the gold standard.
doi:10.1371/journal.pone.0035184.t005
Table 6. Adjuvant systemic treatment received by the patients in 1995–1996 and hypothetical treatment decision based on the
Institut Curie (IC) 2010 guidelines.
Adjuvant systemic treatment received by the patients in 1995–1996 and hypothetical treatment decision based on the Institut Curie 2010
guidelines.
Adjuvant Treatment
no AHT
no ACT AHT
AHT
ACT ACT
All HG2 tumors (n=70)
Adjuvant treatment received in 95–96 60 (85.7%) 8 (11.4%) 2 (2.8%) 0 (-)
IC 2010 treatment guidelines with HG 0 (-) 35 (50%) 31 (44.3%) 4 (5.7%)
IC 2010 treatment guidelines with GG 5 (7.1%) 37 (54.8%) 24 (34.3%) 4 (5.7%)
ER+HER22 HG2 tumors (n=60)
Adjuvant treatment received in 95–96 51 (85%) 8 (13.3%) 1 (1.6%) 0 (-)
IC 2010 treatment guidelines with HG 0 (-) 34 (56.6%) 26 (43.3%) 0 (-)
IC 2010 treatment guidelines with GG 5 (8.3%) 36 (60%) 19 (31.6%) 0 (-)
Treatment decision simulation was based on the histological grade (HG) or the Genomic Grade (GG). AHT: adjuvant hormonal therapy. ACT: adjuvant chemotherapy.
doi:10.1371/journal.pone.0035184.t006
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treatment of breast carcinoma. These figures are consistent with
data generated with other gene expression signatures. Using the
Recurrence Score (OncotypeDX, Genomic Health), Oratz et al
showed a switch from adjuvant hormonal therapy to adjuvant
chemotherapy in 4% and a switch from adjuvant chemotherapy to
adjuvant hormonal therapy in 21% of the cases [28]. For a
hypothetical cohort of 100 patients, Hornberger et al estimated
that a reduction of 200.000$ in treatment costs could be expected
using the Recurrence Score [29]. Reference treatment guidelines
are however a key driver for the impact of gene expression
signatures and prognostic factors in general. Bueno de Mesquita
et al showed the 70-gene signature would result in a higher use of
adjuvant systemic treatment than the rather restrictive Dutch
CBO guidelines whereas it would be the opposite when comparing
the 70-gene signature to the St. Gallen and Nottingham
Prognostic Index guidelines and Adjuvant!Online web-based
decision-making tool [30].
Pathological evaluation of breast tumors is based on the use of
formalin fixed-paraffin embedded (FFPE) tissues. One limitation to
the use of the MapQuant Genomic Grade is the need for a fresh or
frozen tissue section. This is not currently routine practice in most
breast cancer care centres, while preparing several sections for
different assays may represent a challenge with small size tumors
(pT1) that represent a growing proportion of cases at diagnosis.
Moreover, the DNA micro-array technology on which the
MapQuant GG is based requires specific technical platforms
and trained teams, and is still currently a high-cost procedure. To
address these limitations, an FFPE-based PCR Genomic Grade
assay has been developed. A set of 6 genes from the original 97-
gene micro-array GG has been selected, based on high
reclassification concordance with HG and MapQuant GG. The
assay has been validated on a series of 336 breast tumors from a
reference breast cancer care centre: 84% of all cases, and 82% of
HG-2 tumors, were reclassified as GG-1 or GG-3 (in-house data,
and Laios et al, abstract SABCS 2011). Additional prognostic
validation is ongoing on the BIG-98 study cohort.
In a reference comprehensive cancer centre setting, compared
to histological grade, GG added significant information on tumor
cell proliferation in breast cancers where adjuvant treatment
decision-making remains a challenge. In addition, in patients with
histological grade II carcinoma, applying the GG to guide the
treatment scheme could lead to a reduction in the prescription of
adjuvant hormonal therapy and chemotherapy. However, based
on the results observed here and considering (i) the relatively close
prognostic values of GG and Ki67, (ii) the reclassification of about
30% of HG-2 tumors as Equivocal GG and (iii) the economical
and technical requirements of the MapQuant micro-array GG
test, the availability in the near future of a PCR-based Genomic
Grade test with improved performances may lead to an
introduction in clinical routine of this test for histological grade
2, ER positive, HER2 negative breast carcinoma
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Figure S1 Kernel density plot of the Genomic Grade
Index, Mitotic Index and Ki67 score.
(TIF)
Figure S2 Comparison between Genomic Grade Index,
Mitotic Index and Ki67 score. Correlation to metastatic
events. All tumors. Left: scatter plot of Genomic Grade Index
(GGI) and Ki67 score. Red dot: Metastatic progression (29
patients); Black dot: No metastatic progression. Right: scatter plot
of GGI and Mitotic Index. Red dot: Metastatic progression (29
patients); Black dot: No metastatic progression.
(TIF)
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